ConjuChem
From Wikipedia, the free encyclopedia
 |
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (September 2008) |
 |
This article relies on references to primary sources or sources affiliated with the subject, rather than references from independent authors and third-party publications. Please add citations from reliable sources. (September 2008) |
| Type | Public (TSX has Delisted this Stock) |
|---|---|
| Industry | Biotechnology |
| Headquarters | Montreal, Quebec, Canada |
| Key people | Mark Perrin |
| Products | Drug Affinity Construct (DAC) and Preformed Conjugate-Drug Affinity Construct (PC-DAC) |
| Employees | 44[1] |
| Website | www.conjuchem.com |
ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Canada and employs 45 people, 90% of whom are in research and development.
[edit] References
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
